By Adriano Marchese
Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents.
The U.S. District Court of Massachusetts ruled that Pfizer's motion that U.S. Patent Number 11,358,953 is invalid, Enanta said Tuesday.
Through a patent infringement lawsuit, the clinical-stage biotechnology was seeking damages for infringement of the patent in the manufacture, use and sale of Pfizer's Paxlovid.
The court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity.
"Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit," it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 24, 2024 07:24 ET (12:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.